# Maze Therapeutics

> Analysis by Optimly for Optimly AI Visibility, in the Optimly AI Brand Index. Last analyzed June 29, 2026.

> Maze Therapeutics is a biotechnology company focused on developing breakthrough precision medicines for common diseases with large unmet medical needs. They leverage advances in human genetics and a proprietary Compass platform, which utilizes variant functionalization, to design medicines that address genetic drivers of disease, with a strong commitment to kidney disease treatments.

- Business Profile: https://optimly.ai/brand/maze-therapeutics
- Publisher: Optimly (https://optimly.ai)
- Dataset: Optimly AI Brand Index (https://optimly.ai/brand)
- Official website: https://mazetx.com/
- Logo: https://logo.clearbit.com/mazetx.com
- Slug: maze-therapeutics
- Category: Biotechnology
- Last Analyzed: June 29, 2026

## Buyer Intent Signals
Problems: Traditional Drug Discovery: Relying on conventional, lab-based drug screening and preclinical/clinical trials without leveraging advanced genetic analysis or proprietary variant functionalization plat | Contract Research Organizations (CROs): Outsourcing drug discovery and development processes to specialized research organizations, rather than maintaining an in-house genetics platform for precision  | Continue with Standard of Care: Not pursuing the development of new precision medicines for genetically driven diseases, allowing patients to continue with existing treatments that may have limited ef
Solutions: Maze Therapeutics | precision medicine kidney disease | genetic therapeutics | Generic Bioinformatics Software Suites: Utilizing off-the-shelf bioinformatics tools for genetic data analysis without the unique, integrated, and proprietary 'Compass platform' for variant functional